Related Experiment Video
Updated: Aug 16, 2026

An In vitro Co-infection Model to Study Plasmodium falciparum-HIV-1 Interactions in Human Primary Monocyte-derived Immune Cells
Published on: August 15, 2012
[Urinary porphyrin excretion in human immunodeficiency virus infection]
F Mouly1, M Janier, Y Nordmann
1Policlinique de Dermatologie, Hôpital Saint-Louis, Paris.
Insights
Human immunodeficiency virus (HIV) infection is not directly linked to altered porphyrin metabolism. Liver disorders, common in HIV patients, are more likely causes of these metabolic changes.
Area of Science:
- Biochemistry
- Virology
- Hepatology
Context:
- Porphyria cutanea tarda (PCT) is a known complication in some human immunodeficiency virus (HIV) patients.
- Previous reports indicate PCT in approximately 60 HIV-infected individuals since 1987.
- The role of HIV infection in porphyrin metabolism disorders, beyond overt PCT, remains unclear.
Purpose:
- To investigate porphyrin metabolism disorders in HIV-infected patients without clinically apparent PCT.
- To assess urinary porphyrin excretion patterns in a cohort of HIV-positive individuals.
Summary:
- Urinary porphyrin levels were analyzed in 64 HIV-infected patients.
- Abnormal porphyrin excretion was detected in 36% of patients, with 6% showing patterns suggestive of PCT.
- Increased coproporphyrinuria was observed in 23% of patients.
- Abnormalities were more prevalent in patients with existing liver disease or advanced HIV/AIDS.
- One patient later developed PCT, two years after the initial assessment.
Impact:
- HIV infection itself may not directly cause altered porphyrin metabolism.
- The high frequency of liver disorders in HIV patients likely contributes to observed porphyrin abnormalities.
- Findings suggest that underlying hepatopathy is a significant factor in porphyrin metabolism disturbances among HIV-infected individuals.
Objectives:
Porphyria cutanea tarda has been reported in about 60 patients with human immunodeficiency virus (HIV) since 1987. We looked for porphyrin metabolism disorders in HIV infected patients without patent porphyria cutanea tarda.
Methods:
Urinary porphyrin excretion was measured in 64 patients with an HIV infection.
Results:
Excreted levels were abnormal in 23 patients (36%) including 4 (6%) with patterns highly suggestive of porphyria cutanea tarda. One of these patients developed the disease 2 years later. In 15 patients (23%) there was a significant increase in coproporphyrinuria. Minimal alterations in uroporphyrin or its precursors were seen in the other patients. Abnormal excretion was significantly more frequent in patients with hepatopathy and in patients who had progressed to AIDS.
Conclusion:
Our findings suggest that HIV infection does not play a direct role in altered porphyrin metabolism because of the frequency of liver disorders observed in these patients.
Related Concept Videos
Drug Elimination by Renal Route: Tubular Reabsorption
Drug Elimination by Renal Route: Tubular Secretion
Renal Drug Excretion: Tubular Secretion
Pharmacokinetics in Pediatric Patients: Drug Excretion
Urinary Tract Infection II: Pathophysiology
Urine Studies I: Urinalysis

